- Home
- IFRX vs TSQ Comparison
IFRX vs TSQ Comparison
Compare IFRX & TSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- TSQ
- Stock Information
- Founded
- IFRX 2007
- TSQ 1996
- Country
- IFRX Germany
- TSQ United States
- Employees
- IFRX N/A
- TSQ N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- TSQ Broadcasting
- Sector
- IFRX Health Care
- TSQ Consumer Discretionary
- Exchange
- IFRX Nasdaq
- TSQ Nasdaq
- Market Cap
- IFRX 117.8M
- TSQ 131.9M
- IPO Year
- IFRX 2017
- TSQ 2000
- Fundamental
- Price
- IFRX $1.15
- TSQ $7.61
- Analyst Decision
- IFRX Strong Buy
- TSQ Strong Buy
- Analyst Count
- IFRX 1
- TSQ 3
- Target Price
- IFRX $8.00
- TSQ $16.83
- AVG Volume (30 Days)
- IFRX 623.9K
- TSQ 44.1K
- Earning Date
- IFRX 05-07-2025
- TSQ 05-08-2025
- Dividend Yield
- IFRX N/A
- TSQ 10.37%
- EPS Growth
- IFRX N/A
- TSQ N/A
- EPS
- IFRX N/A
- TSQ N/A
- Revenue
- IFRX $187,930.00
- TSQ $447,955,000.00
- Revenue This Year
- IFRX $396.02
- TSQ N/A
- Revenue Next Year
- IFRX $155.22
- TSQ $0.24
- P/E Ratio
- IFRX N/A
- TSQ N/A
- Revenue Growth
- IFRX 177.12
- TSQ N/A
- 52 Week Low
- IFRX $1.14
- TSQ $7.57
- 52 Week High
- IFRX $2.82
- TSQ $13.57
- Technical
- Relative Strength Index (RSI)
- IFRX 24.46
- TSQ 27.16
- Support Level
- IFRX $1.76
- TSQ $7.85
- Resistance Level
- IFRX $1.34
- TSQ $8.00
- Average True Range (ATR)
- IFRX 0.14
- TSQ 0.26
- MACD
- IFRX -0.01
- TSQ -0.06
- Stochastic Oscillator
- IFRX 1.39
- TSQ 3.79
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About TSQ Townsquare Media Inc.
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.